Effect of thalidomide on bone marrow angiogenesis in multiple myeloma patients
Cury, Priscilla Cury de Camargo; Higashi, Fabiana; Zacchi, Flávia Fernandes Silva; Palhares, Renata Bacic; Quero, Adriana Alvares; Dias, Ana Luiza Miranda Silva; Crusué, Edvan de Queiroz; Hungria, Vania Tietsche de Moraes.
Hematol., Transfus. Cell Ther. (Impr.)
; 42(2): 159-163, Apr.-June 2020. ilus, tab
Artículo
Inglés
| SES-SP, SES SP - Instituto de Infectologia Emílio Ribas, SES-SP | ID: biblio-1097417
BACKGROUND:
Bone marrow angiogenesis is increased in multiple myeloma (MM) patients,prompting the rationale for using antiangiogenic drugs in the treatment of these patients.OBJECTIVE:
To assess angiogenesis in patients with MM at diagnosis and following treatmentwith an antiangiogenic drug.Patients andMethods:
Twenty-three patients with newly diagnosed MM were treated withthalidomide-based regimens. Bone marrow evaluation was made before and following treat-ment and included angiogenesis assessment, which was quantified through microvesseldensity (MVD) determination, by means of anti-CD34 immunohistochemical labeling, andclassified either as high MVD or low MVD, according to the mean CD34 count above or belowthe median of 12.6.RESULTS:
The pre-therapy median MVD was 12 (7.518.3) versus 8.7 (5.3518.5) post-therapy,p = 0.2114.CONCLUSIONS:
Our study found no reduction in MVD before and following treatment and,accordingly, we could establish no relationship between MVD and response to therapy inthe sample we studied.
Biblioteca responsable:
BR31.1
Ubicación: BR31.1; 2020_P-016
Texto completo
Documentos relacionados
